20,160 and the sleep machines pulled from bedrooms

20,160 is the number at the center. Those BMC Luna G3 APAP Model LG3600 units were subject to a Class I recall in the United States, after revised Food and Drug Administration guidance dated January 6, 2026 restated when low risk lifestyle products sit outside strict device enforcement.

The guidance carries the title General Wellness: Policy for Low Risk Devices. It takes the place of the 2019 guidance and looks at low risk products that support a healthy lifestyle.

Software features made only to maintain or encourage a healthy lifestyle with no tie to diagnosis, cure, mitigation, prevention or treatment sit outside the medical device definition under Section 520(o)(1)(B). Non software products with that same purpose get enforcement discretion, meaning the agency does not plan to enforce requirements under the Federal Food, Drug, and Cosmetic Act.

Drugs, biologics, dietary supplements, foods, and cosmetics handled by other FDA Centers stay outside the policy, as do combination products. Non-invasive products that estimate blood pressure for wellness purposes can qualify when the intended use stays strictly wellness centered and the remaining conditions are satisfied.

A wearable that estimates blood glucose to track nutritional effects can qualify when it is specifically contraindicated for people with diabetes and pre-diabetes. A blood glucose wearable that relies on minimally invasive microneedle technology does not count as low risk even when its claims speak only of wellness.

Sensor based wellness products lose general wellness status when they prompt defined clinical action, offer treatment guidance, or measure for screening, diagnosis, monitoring or management of disease. They also lose that status when they claim to replace an FDA cleared device or when they refer to named diseases or diagnostic thresholds.

The Luna G3 APAP recall marked where that boundary holds. BMC Medical Co., Ltd. reported the recall on July 15, 2026 after identifying a firmware defect, and FDA listed Recall Number Z-2979-2026.

Firmware version G3-2.00.76 could produce an error message followed by automatic shutdown and loss of therapy delivery under high pressure, high respiratory rate and high peak flow. BMC updated firmware to version G3-2.00.77 for 20,160 devices at the United States importers warehouse from October through December 2024, then later found potentially up to 196 units may have missed the update. BMC had received no complaints or serious adverse reports as of the September 8, 2026 notice. It remains unknown whether any unupdated units are still in use.

Forecasts suggest continued growth on the wellness side of that line. The North America medical wellness devices market holds a 2026 value of US$44.4 billion and is expected to reach US$71.8 billion by 2033 at a compound annual growth rate of 7.1 percent. The United States is anticipated to hold 80 percent market share in 2026, while Canada is described as the fastest growing region.

Diabetic monitoring devices are projected to hold 37 percent of revenue share in 2026, and retail sales are anticipated to account for over 62 percent. Consumer grade devices still face questions about inconsistent readings relative to hospital grade equipment, along with data privacy concerns.

Watch next whether actual 2026 retail sales align with forecasts, and how validation guardrails settle for everyday trackers.